Eliana Merle
Stock Analyst at Barclays
(3.31)
# 1,008
Out of 5,245 analysts
103
Total ratings
44.83%
Success rate
4.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eliana Merle
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Maintains: Underweight | $0.3 → $0.28 | $0.2101 | +33.27% | 6 | May 19, 2026 | |
| MBX MBX Biosciences | Maintains: Overweight | $66 → $70 | $31.85 | +119.78% | 2 | May 12, 2026 | |
| ASND Ascendis Pharma | Maintains: Overweight | $342 → $345 | $247.05 | +39.65% | 4 | May 11, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $607 → $615 | $434.52 | +41.54% | 3 | May 6, 2026 | |
| MRNA Moderna | Maintains: Neutral | $36 → $45 | $46.88 | -4.01% | 11 | May 4, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $923 → $917 | $638.88 | +43.53% | 2 | Apr 30, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $106 → $115 | $75.56 | +52.20% | 2 | Apr 30, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $44 → $43 | $23.39 | +83.84% | 1 | Apr 29, 2026 | |
| INSM Insmed | Maintains: Overweight | $231 → $237 | $106.24 | +123.08% | 2 | Apr 1, 2026 | |
| QURE uniQure | Maintains: Equal-Weight | $31 → $25 | $24.19 | +3.35% | 6 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $105 | $54.09 | +94.12% | 4 | Mar 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $56 | $41.62 | +34.55% | 2 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $59 | $32.47 | +81.71% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $8 | $7.09 | +12.83% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $68 → $119 | $68.81 | +72.94% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $964 | $517.26 | +86.37% | 6 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $5.07 | +255.03% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $8.60 | +283.72% | 1 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $80 | $69.12 | +15.74% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $527 | $297.45 | +77.17% | 4 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | $2.90 | +727.59% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $20 | $59.71 | -66.50% | 5 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $12 | $16.80 | -28.57% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $8 | $1.75 | +357.14% | 1 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $74 → $21 | $9.09 | +131.02% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $70 | $78.89 | -11.27% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $2.2 | $4.06 | -45.81% | 4 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $71 | $151.56 | -53.15% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $97 → $131 | $92.14 | +42.17% | 6 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $5 | $36.23 | -86.20% | 3 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $18.81 | +16.96% | 1 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $47 | $6.35 | +640.16% | 1 | Jun 23, 2022 |
Gossamer Bio
May 19, 2026
Maintains: Underweight
Price Target: $0.3 → $0.28
Current: $0.2101
Upside: +33.27%
MBX Biosciences
May 12, 2026
Maintains: Overweight
Price Target: $66 → $70
Current: $31.85
Upside: +119.78%
Ascendis Pharma
May 11, 2026
Maintains: Overweight
Price Target: $342 → $345
Current: $247.05
Upside: +39.65%
Vertex Pharmaceuticals
May 6, 2026
Maintains: Overweight
Price Target: $607 → $615
Current: $434.52
Upside: +41.54%
Moderna
May 4, 2026
Maintains: Neutral
Price Target: $36 → $45
Current: $46.88
Upside: -4.01%
Regeneron Pharmaceuticals
Apr 30, 2026
Maintains: Overweight
Price Target: $923 → $917
Current: $638.88
Upside: +43.53%
Ionis Pharmaceuticals
Apr 30, 2026
Maintains: Overweight
Price Target: $106 → $115
Current: $75.56
Upside: +52.20%
Ultragenyx Pharmaceutical
Apr 29, 2026
Maintains: Overweight
Price Target: $44 → $43
Current: $23.39
Upside: +83.84%
Insmed
Apr 1, 2026
Maintains: Overweight
Price Target: $231 → $237
Current: $106.24
Upside: +123.08%
uniQure
Mar 23, 2026
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $24.19
Upside: +3.35%
Mar 4, 2026
Maintains: Overweight
Price Target: $80 → $105
Current: $54.09
Upside: +94.12%
Mar 2, 2026
Maintains: Overweight
Price Target: $69 → $56
Current: $41.62
Upside: +34.55%
Jan 28, 2026
Initiates: Overweight
Price Target: $59
Current: $32.47
Upside: +81.71%
Jan 28, 2026
Initiates: Equal-Weight
Price Target: $8
Current: $7.09
Upside: +12.83%
Jan 28, 2026
Upgrades: Overweight
Price Target: $68 → $119
Current: $68.81
Upside: +72.94%
Jan 28, 2026
Initiates: Overweight
Price Target: $964
Current: $517.26
Upside: +86.37%
Jan 28, 2026
Initiates: Overweight
Price Target: $18
Current: $5.07
Upside: +255.03%
Jan 28, 2026
Initiates: Overweight
Price Target: $33
Current: $8.60
Upside: +283.72%
Jan 28, 2026
Initiates: Overweight
Price Target: $80
Current: $69.12
Upside: +15.74%
Jan 28, 2026
Initiates: Overweight
Price Target: $527
Current: $297.45
Upside: +77.17%
Aug 13, 2025
Maintains: Buy
Price Target: $26 → $24
Current: $2.90
Upside: +727.59%
Aug 12, 2025
Maintains: Neutral
Price Target: $18 → $20
Current: $59.71
Upside: -66.50%
Jul 21, 2025
Downgrades: Neutral
Price Target: $45 → $12
Current: $16.80
Upside: -28.57%
Jul 15, 2025
Maintains: Buy
Price Target: $4 → $8
Current: $1.75
Upside: +357.14%
May 15, 2025
Maintains: Buy
Price Target: $74 → $21
Current: $9.09
Upside: +131.02%
May 13, 2025
Maintains: Buy
Price Target: $72 → $70
Current: $78.89
Upside: -11.27%
Jan 28, 2025
Maintains: Neutral
Price Target: $5 → $2.2
Current: $4.06
Upside: -45.81%
Jan 8, 2025
Maintains: Buy
Price Target: $65 → $71
Current: $151.56
Upside: -53.15%
Sep 18, 2024
Maintains: Neutral
Price Target: $97 → $131
Current: $92.14
Upside: +42.17%
Apr 4, 2024
Maintains: Neutral
Price Target: $3 → $5
Current: $36.23
Upside: -86.20%
Oct 13, 2022
Initiates: Buy
Price Target: $22
Current: $18.81
Upside: +16.96%
Jun 23, 2022
Maintains: Buy
Price Target: $51 → $47
Current: $6.35
Upside: +640.16%